Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,382.14
(
0.21%
)
US TECH 100
22,508.40
(
0.02%
)
Dow Jones
45,403.58
(
0.52%
)
Brent Oil
107.52
(
-0.68%
)
Bitcoin
67,083.39
(
1.71%
)
News Focus
News Focus
Post# of 257306
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122821
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: jq1234 post# 173602

Friday, 01/31/2014 6:03:53 PM

Friday, January 31, 2014 6:03:53 PM

Post# of 257306
It’s just common sense, IMO, that ribavirin should be included for cirrhotic patients if there is any doubt at all about its utility. (This is a separate matter from 8w-vs-12w dosing or the addition of a third DAA by GILD.)

Bottom line (re-iterated): I think it will be hard for GILD (or anyone else) to top the data from TURQUOISE-2.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today